Abstract
Aims Targeting tumor metabolism may improve the outcomes for patients with glioblastoma (GBM). To further preclinical efforts targeting metabolism in GBM, we tested the hypothesis that brain tumors can be stratified into distinct metabolic groups with different patient outcomes. Therefore, to determine if tumor metabolites relate to patient survival, we profiled the metabolomes of human gliomas and correlated metabolic information with clinical data.
Results We found that isocitrate dehydrogenase-wildtype (IDHwt) GBMs are metabolically distinguishable from IDH mutated (IDHmut) astrocytomas and oligodendrogliomas. Survival of patients with IDHmut gliomas was expectedly more favorable than those with IDHwt GBM, and metabolic signatures can stratify IDHwt GBMs subtypes with varying prognoses. Patients whose GBMs were enriched in amino acids had improved survival while those whose tumors were enriched for nucleobases and carbohydrates fared more poorly. These findings were recapitulated in validation cohorts using both metabolomic and transcriptomic data.
Innovation Our results suggest the existence of metabolic subtypes of GBM with differing prognoses and further support the concept that metabolism may drive the aggressiveness of human gliomas.
Conclusions Our data show that metabolic signatures of human gliomas can inform patient survival. These findings may be used clinically to tailor novel metabolically targeted agents for GBM patients with different metabolic phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.J.S. was supported by the NCI (F32CA260735). L.O.C. was supported by the NCI (T32CA140044) and the NIAID (T32AI007413). S.A.C. was supported by the Rogel Cancer Center Core Grant and the Dr. Frank Limpert Career Development Fund at the University of Michigan Rogel Cancer Center. D.O. was supported by the NCI (R01CA226527). J.E.I. was supported by the NCI (R00CA218869 and R21CA242221). P.C. was supported by the NINDS (R01NS110838 and R21NS090087), American Cancer Society grant RSG1102901, and Bankhead-Coley Cancer Research Program. A.R. was supported by the NCI (R37CA214955), MIDAS PODS grant, MICDE Catalyst grant, and institutional startup funds from the University of Michigan Ann Arbor. C.A.L. was supported by the NCI (R01CA244931) and UMCCC Core Grant (P30CA046592). D.R.W. was supported by the NCI (K08CA234416 and R37CA258346), Cancer Center Support Grant P30CA46592, Damon Runyon Cancer Foundation, Ben and Catherine Ivy Foundation and the Sontag Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of University of Michigan Medical School (IRBMED) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
